Net Present Value Model: Soliris
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Soliris Drug Details
Eculizumab (Soliris) is a humanized monoclonal antibody directed against terminal complement protein C5. Soliris is formulated as injectable concentrated solution and injectable solution for intravenous route of administration. Soliris is indicated for the treatment of paroxysmal nocturnal hemoglobinuria in patients without a history of transfusion, atypical hemolytic uremic syndrome, for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy and for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Soliris (eculizumab) also indicated to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive, and for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.Eculizumab is also under development for the treatment of liver transplant rejection, relapsing neuromyelitis optica spectrum disorder (NMOSD), Guillain-Barre Syndrome and for the treatment of brain injury in patients with aneurysmal subarachnoid hemorrhage and coronavirus disease 2019 (COVID-19) pneumonia, coronavirus disease 2019 (COVID-19) associated acute lung injury, coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome.It was also under development for the prevention of antibody mediated rejection (AMR) in presensitized kidney transplant patients, treatment of membranoproliferative glomerulonephritis (MPGN type II, dense deposit disease), C3 glomerulonephritis (C3GN), allergic asthma, psoriasis, anti-neutrophil cytoplasmic antibody-associated vasculitis, dermatomyositis, Shiga-toxin producing Escherichia Coli hemolytic-uremic syndrome (STEC-HUS), rheumatoid arthritis and dry age-related macular degeneration,cold agglutinin disease and for the prevention of delayed kidney transplant graft function (DGF) after solid organ transplantation.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.